Maravai LifeSciences Holdings Inc
MRVI
ISIN null / Valor 58353451
Maravai LifeSciences Holdings Inc
UMushroom community rating:
About company
Maravai LifeSciences Holdings Inc is a prominent player in the biopharmaceutical sector, providing critical support to biopharmaceutical companies and contract development and manufacturing organizations worldwide. Through its subsidiary, Cygnus Technologies, Maravai LifeSciences specializes in enhancing the biopharmaceutical development process by ensuring the purity and safety of a wide range of therapeutic products. These include antibodies, proteins, gene therapies, vaccines, and plasma derivatives. The company's expertise and services are integral to the successful development, manufacturing, and commercialization of these therapeutic solutions, addressing a crucial need in the biopharmaceutical industry for high-quality, reliable analytical tools and methodologies.
Summarized from source with an LLMView SourceSector: TechnologyLatest Results (06.11.2025):
Maravai LifeSciences Holdings Inc reported its first quarter 2025 financial results, with total revenue of $46.9 million and a net loss of $(52.9) million – which includes a $12.4 million goodwill impairment – while delivering an adjusted EBITDA of $(10.5) million. The earnings report highlighted a 27.0% decrease in revenue compared to the first quarter of 2024, mainly due to a significant reduction in Nucleic Acid Production orders, even as the company reaffirmed its full-year 2025 revenue guidance between $185.0 million and $205.0 million.
Revenue Overview
In the first quarter of 2025, Maravai LifeSciences Holdings Inc achieved $46.9 million in revenue, marking a 27.0% decline year-over-year. This drop reflects notably lower orders in Nucleic Acid Production.
Segment Performance
Nucleic Acid Production revenue fell to $28.8 million, a 37.5% decline, primarily impacted by fewer high-volume CleanCap® orders for commercial-phase vaccine programs, while Biologics Safety Testing revenue remained relatively flat at $18.1 million.
Earnings & EBITDA
The company reported a net loss of $(52.9) million for the quarter, which includes a goodwill impairment of $12.4 million. The adjusted EBITDA for the quarter stood at $(10.5) million, a marked turnaround from the previous year’s positive performance.
Guidance & Outlook
Maravai LifeSciences Holdings Inc maintained its full-year 2025 revenue guidance in the range of $185.0 million to $205.0 million, underscoring its confidence in the base business despite fluctuations in high-volume CleanCap orders and ongoing market challenges.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
543 M
Market cap (USD)
2,460,596
Daily traded volume (Shares)
5.61 / 5.41
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
